Weekly Buzz: VRTX, APTX Gain FDA Nod; UNCY Disappoints; Ipsen Opens Wallet; VTGN Misses Goalrttnews·Jul 2 at 09:15 AMNVS-0.72%VRTX+0.90%
VistaGen Therapeutics (VTGN) Receives a Rating Update from a Top AnalystTip Ranks·Jul 1 at 02:55 AMVTGN+0.18%
Penny Stock Vistagen Keeps Regulatory Plans Alive Despite Anxiety Study Missbenzinga_article·Jun 30 at 12:35 PMVTGN+0.18%
12 Health Care Stocks Moving In Tuesday's Intraday Sessionbenzinga_article·Jun 30 at 12:05 PMCELZ-4.00%VTGN+0.18%
Nasdaq Gains Over 300 Points; Chicago PMI Falls In Junebenzinga_article·Jun 30 at 11:08 AMVTGN+0.18%CELZ-4.00%
VTGN: Fasedienol missed primary endpoints in Phase 3, but showed promise in severe social anxiety subgroupQuartr·Jun 30 at 07:18 AMVTGN+0.18%
VistaGen says fasedienol misses primary endpoint in PALISADE-4 Phase 3 social anxiety trialPUBT·Jun 30 at 07:02 AMVTGN+0.18%
VistaGen directors FitzPatrick, Curley to step down after 2026 annual meetingPUBT·Jun 17 at 04:14 PMVTGN+0.18%
Vistagen Therapeutics’ 2026 Workforce Cuts Raise Execution Risks and Threaten Long-Term GrowthTip Ranks·Jun 17 at 01:00 AMVTGN+0.18%
